Semaglutide vs Tirzepatide for Weight Loss: Which Works Better in 2026?

Both drugs work. Both are weekly injections. Both cost over $1,000/month without insurance. But the clinical data shows meaningful differences — especially on weight loss outcomes. Here's what the trials actually say.

Updated April 2026 · 8 min read

How They Work: GLP-1 vs. Dual GIP/GLP-1

Semaglutide is a GLP-1 receptor agonist. It mimics the hormone glucagon-like peptide-1, which is released after eating. GLP-1 signals the brain to reduce appetite, slows gastric emptying so food stays in the stomach longer (increasing fullness), and stimulates insulin secretion in a glucose-dependent way. The result: you eat less, feel full sooner, and your blood sugar improves.

Tirzepatide adds a second mechanism. It also activates the GIP (glucose-dependent insulinotropic peptide) receptor. GIP is another incretin hormone that influences fat storage, energy expenditure, and insulin sensitivity. By activating both receptors simultaneously, tirzepatide appears to produce synergistic metabolic effects that exceed GLP-1 agonism alone.

In simple terms: semaglutide hits one target; tirzepatide hits two. The additional target appears to be responsible for the larger average weight loss seen in tirzepatide trials.

Weight Loss Results: What the Trials Show

The key trials are STEP-1 (semaglutide, 2021) and SURMOUNT-1 (tirzepatide, 2022). Both studied non-diabetic adults with obesity over roughly 68 weeks.

• STEP-1 (Wegovy 2.4mg): Average weight loss of 14.9% body weight. About 86% of participants lost ≥5% of body weight; 70% lost ≥10%.
• SURMOUNT-1 (Zepbound 15mg): Average weight loss of 20.9% body weight. About 91% lost ≥5%; 57% lost ≥20% of body weight.

The difference is meaningful. At population level, tirzepatide patients lost roughly 6 additional percentage points of body weight. For a 220-pound person, that's about 13 extra pounds on average.

The SURMOUNT-5 trial (published 2025) provided the first direct head-to-head comparison of tirzepatide vs. semaglutide. It confirmed tirzepatide's advantage: participants on tirzepatide lost an average of 20.2% vs. 13.7% for semaglutide — a statistically significant difference of roughly 47% more weight lost.

Important caveat: these are averages. Individual response varies substantially. Some patients achieve much better results on semaglutide, and not everyone tolerates tirzepatide's higher doses. A meaningful minority of patients on either drug achieve less than 5% weight loss.

Side Effects: What to Expect from Each

Both drugs share the same class of GI side effects because both slow gastric emptying. Nausea is the most common — especially during the dose escalation phase (the first 3–6 months as you ramp up from starting dose to maintenance dose).

Some comparative analyses suggest tirzepatide may produce slightly less nausea than semaglutide at equivalent weight-loss doses, though this is not consistently demonstrated across all studies. Both carry class-level warnings: possible thyroid C-cell tumors (observed in rodents, not confirmed in humans), risk of pancreatitis, and contraindication in personal/family history of medullary thyroid carcinoma or MEN2.

Muscle mass loss during rapid weight loss is a concern with both drugs. Some protocols add resistance training or protein supplementation to mitigate this. The clinical significance of lean mass loss observed in GLP-1 trials remains an active area of research.

Cost Comparison: What You'll Actually Pay

Branded list prices favor tirzepatide slightly: Zepbound runs about $1,059/month vs. Wegovy at $1,349/month. However, actual out-of-pocket cost depends heavily on insurance coverage and savings programs.

Eli Lilly's Zepbound savings card caps out-of-pocket at $550/month for commercially insured patients with coverage, and Novo Nordisk offers a similar program for Wegovy. Neither drug is well-covered by most commercial insurance for obesity (as opposed to diabetes), which means many patients pay full list price or pay the savings card cap without insurance applying.

Compounded versions of both are available through telehealth platforms:

• Compounded semaglutide: $100–$300/month from licensed 503A telehealth programs
• Compounded tirzepatide: $150–$350/month from licensed 503A telehealth programs

Use the GLP-1 out-of-pocket calculator to estimate what you'd pay for either drug based on your insurance situation.

Cardiovascular and Long-Term Data

Semaglutide has more long-term cardiovascular data. The SUSTAIN-6 trial (2016) showed cardiovascular risk reduction in diabetic patients. The SELECT trial (2023) showed a 20% reduction in major cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease — a major milestone that influenced FDA approval language and insurance coverage decisions.

Tirzepatide's cardiovascular outcome trial (SURMOUNT-MMO) was still ongoing as of early 2026. Preliminary data is promising, but tirzepatide doesn't yet have the same breadth of long-term cardiovascular data as semaglutide. For patients whose primary motivation is cardiovascular risk reduction alongside weight loss, semaglutide currently has a stronger evidence base in this specific area.

Both drugs show improvements in blood pressure, triglycerides, and HbA1c. Tirzepatide shows somewhat better improvements in insulin sensitivity and lipid profiles in trials, consistent with its dual mechanism.

Which Should You Choose?

This is a medical decision that should involve your doctor, but here's a framework based on the evidence:

For most patients choosing between compounded versions through a telehealth program, the difference in average outcomes is real but not determinative — individual variation means either drug could work well for you. Start with whichever your provider recommends based on your full health history.

Frequently Asked Questions